A second trial is recruiting patients to determine the side effects and best dose of pembrolizumab and the MEK inhibitor trametinib for recurrent KRAS-mutated NSCLC that is metastatic, unresectable or locally advanced (NCT03299088, NCT03225664). Here, KRAS is linked to non-small cell lung carcinoma.